Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench
- PMID: 34473198
- DOI: 10.1001/jamaoncol.2021.3369
Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench
Comment on
-
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.JAMA Oncol. 2021 Nov 1;7(11):1617-1625. doi: 10.1001/jamaoncol.2021.3523. JAMA Oncol. 2021. PMID: 34473194 Free PMC article. Clinical Trial.
Similar articles
-
Complete pathological remission after neoadjuvant ensartinib in patients with locally advanced lung adenocarcinoma and with CTLC-ALK and ALK-DHX8 rearrangements.Eur J Cancer. 2022 Jul;169:131-134. doi: 10.1016/j.ejca.2022.04.012. Epub 2022 May 11. Eur J Cancer. 2022. PMID: 35567918 No abstract available.
-
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report.World J Surg Oncol. 2023 Mar 2;21(1):74. doi: 10.1186/s12957-023-02935-9. World J Surg Oncol. 2023. PMID: 36864442 Free PMC article.
-
Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC.Chin Clin Oncol. 2019 Oct;8(S1):S4. doi: 10.21037/cco.2018.10.12. Epub 2018 Nov 9. Chin Clin Oncol. 2019. PMID: 30525756 No abstract available.
-
[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):719-729. doi: 10.3779/j.issn.1009-3419.2020.102.34. Zhongguo Fei Ai Za Zhi. 2020. PMID: 32838492 Free PMC article. Review. Chinese.
-
Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.Future Oncol. 2018 Aug;14(18):1781-1787. doi: 10.2217/fon-2017-0619. Epub 2018 Mar 6. Future Oncol. 2018. PMID: 29506392 Review.
Cited by
-
Targeting MET in NSCLC: An Ever-Expanding Territory.JTO Clin Res Rep. 2024 Jan 3;5(2):100630. doi: 10.1016/j.jtocrr.2023.100630. eCollection 2024 Feb. JTO Clin Res Rep. 2024. PMID: 38361739 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
